==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb

This page displays user query in tabular form.

1836 details
Primary information
ThPP IDTh1225
Therapeutic Peptide/Protein NameCoagulation factor X human
SequenceNA view full sequnce in fasta
Functional ClassificationIb
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half LifeNA
DescriptionNA
Indication/DiseaseNA
PharmacodynamicsThe active substance in Coagadex is human factor X isolated from the plasma of blood donors. It replaces the missing factor X, thereby helping the blood to clot and giving temporary control of bleeding.
Mechanism of ActionPatients with hereditary factor X deficiency lack factor X, a protein needed to form the scab (blood clot) that stops wounds from bleeding. In these patients, blood clots do not form properly, resulting in longer bleeding time and poor wound healing. Blood may seep into surrounding tissues, resulting in local pain and swelling. Bleeding may also occur in internal organs. The active substance in Coagadex is human factor X isolated from the plasma of blood donors. It replaces the missing factor X, thereby helping the blood to clot and giving temporary control of bleeding.
ToxicityNA
MetabolismNA
AbsorptionNA
Volume of DistributionNA
ClearanceNA
CategoriesBlood Coagulation Factors
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Information of corresponding available drug in the market
Brand NameCoagadex
CompanyNA
Brand DiscriptionCOAGADEX, a plasma-derived blood coagulation factor X concentrate,
Prescribed forIt is used for the treatment and prevention of bleeding (including during and after an operation) in patients with hereditary factor X deficiency. Factor X deficiency is a bleeding disorder caused by lack of factor X, a protein needed for normal clotting of the blood.
Chemical NameNA
FormulationNA
Physcial Appearncepowder and solvent used to make a solution
Route of AdministrationIntravenous
Recommended Dosage Dose(IU)=body weight(kg)xdesired factor X rise(IU/dL or % of normal)x0.5(IU/kg/(IU/dL)
ContraindicationHypersensitivity to the active substance
Side EffectsThe most common side effects with Coagadex (which may affect up to 1 in 10 people) are pain or redness at the injection site, fatigue (tiredness), and back pain.
Useful Linkhttp://www.coagadex.com/about-coagadex , http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003855/human_med_001967.jsp&mid=WC0b01ac058001d124
PubMed ID11867437
3-D StructureN.A.